In its Q4 2025 investor letter, Conestoga Capital Advisors highlighted West Pharmaceutical Services (WST) as a company rebounding to sustainable volume growth, despite the fund's overall quarterly underperformance against its benchmark.
While Vertex's expansion into gene therapy and pain management grabs headlines, its enduring dominance and innovation in the cystic fibrosis market remains the core reason long-term investors are holding tight.
With a robust commercial portfolio led by Dupixent and a deep pipeline of late-stage candidates, Regeneron Pharmaceuticals presents a compelling case for sustained growth, trading at a discount to recent valuations.
Amid a cautious market environment, investors are sifting through smaller-cap opportunities. We examine three global penny stocks—two from China's pharmaceutical sector and one from the wine industry—that present a mix of financial resilience and significant challenges.
Collegium Pharmaceutical (COLL) emerged as a standout performer in Third Avenue Small-Cap Value Fund's portfolio, driving gains after the pain management specialist posted robust quarterly results. The fund's latest investor letter details its successful 2025 strategy and highlights COLL's significant contribution.
Collegium Pharmaceutical (COLL) is set to release its fourth-quarter earnings before the bell on Thursday, with analysts anticipating a slowdown in revenue growth against a backdrop of mixed performances in the branded pharmaceuticals sector.
As West Pharmaceutical Services prepares to report its quarterly results, investors are weighing its recent stock decline against a backdrop of sector volatility and macroeconomic uncertainty. Here's what to watch for in Thursday's report.
As Treasury yield curves steepen, signaling bond market concerns over future inflation, investors are looking for resilient holdings. We analyze three companies positioned to navigate potential Fed policy shifts and market volatility.
While low-beta stocks offer a haven in turbulent markets, not all are created equal. We analyze one steady performer with enduring appeal and two whose stable metrics may mask underlying challenges for long-term investors.
Sphera Funds Management increases its stake in the oncology-focused biotech, signaling confidence as the company's two approved therapies drive revenue past $172 million and shares surge over 80%.
Shares of major Japanese pharmaceutical firms tumbled in early Tokyo trading following the launch of a U.S. government website offering discounted prescription drugs, a move seen as potentially disrupting global pricing models.
Despite a 1,300% stock rally, Vestal Point Capital has taken a major $182 million position in clinical-stage biotech Terns Pharmaceuticals, signaling strong confidence in its pipeline targeting NASH, obesity, and metabolic diseases.
Amneal Pharmaceuticals (NYSE: AMRX) presents a complex investment case, with a DCF model suggesting significant undervaluation while traditional P/E metrics signal overvaluation. This analysis unpacks the conflicting signals and explores the factors behind the stock's recent slide.
Viatris (VTRS) is set to report fourth-quarter earnings before the bell on Thursday, with investors watching for signs of stability after a period of mixed performance against its pharmaceutical peers.
Clarity Pharmaceuticals (ASX:CU6) has reignited investor interest with positive Phase II trial results for its novel prostate cancer imaging agent. While the data is promising, the stock's recent rally against a backdrop of annual declines and a high price-to-book ratio presents a complex picture for market participants.
Amidst a cautiously optimistic regional market climate, investors are turning their attention to high-potential, smaller-cap equities. We analyze three standout performers, including pharmaceutical leader Julphar, that combine financial resilience with compelling growth narratives.
As a sell-off rattles high-growth tech and biotech sectors, Ark Invest's Cathie Wood has significantly added to positions in Figma, CoreWeave, and Recursion Pharmaceuticals, betting on a rebound for stocks trading far below recent peaks.
A broad afternoon rally swept U.S. equity markets on Wednesday, fueled by falling crude oil prices that alleviated near-term inflation concerns. Healthcare and pharmaceutical stocks, including BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health, were among the notable gainers.
While the healthcare sector has mirrored broader market gains, heightened regulatory scrutiny and valuation pressures are creating a precarious path for some industry players. We examine three specific stocks where investors may want to exercise caution.
While mid-cap stocks often represent a sweet spot of growth and stability, not all are poised for success. We examine three companies—Oshkosh, Centene, and West Pharmaceutical Services—where valuation concerns and competitive pressures suggest caution may be warranted.
